Vardenafil and organic nitrate medicines must not be used together. This is an explicit contraindication in U.S. prescribing information, not a minor interaction that can be overcome by choosing a lower tablet strength. Vardenafil increases signaling through the nitric-oxide/cGMP pathway, while nitrate medicines also act on that pathway. Combining them can produce a potentially dangerous fall in blood pressure.
The issue is especially important for people who take nitroglycerin for chest pain, isosorbide medicines, or certain recreational nitrites. Some people use nitrates only intermittently and may overlook them when completing a medication questionnaire. Every nitrate exposure matters when a clinician evaluates whether vardenafil is appropriate.
This page focuses exclusively on the contraindicated nitrate combination and emergency communication. For the broader list of interactions—including riociguat, CYP3A4 inhibitors and QT-related medicines—read the drug-interaction hub. This information does not replace emergency instructions from medical professionals.
Vardenafil inhibits phosphodiesterase type 5, allowing cGMP signaling to persist. Organic nitrates supply nitric-oxide-related signaling that also increases cGMP. Combined effects on vascular smooth muscle can cause a much greater vasodilatory response than either mechanism considered alone.
Severe hypotension can lead to dizziness, fainting, inadequate blood flow to organs and potentially serious cardiac or neurologic outcomes. The possible consequences make this combination categorically different from a mild, self-limited side effect.
| Exposure or situation | Why it matters | Appropriate response |
|---|---|---|
| Nitroglycerin tablets or spray | Nitrate used for chest-pain relief | Do not combine; emergency care for chest pain |
| Isosorbide mononitrate/dinitrate | Scheduled or intermittent organic nitrate treatment | Contraindicated with vardenafil |
| Recreational nitrites (“poppers”) | Can supply nitric-oxide/nitrite exposure | Do not combine |
| Chest pain after recent vardenafil | Emergency clinicians must know about the PDE5 inhibitor | Seek emergency assessment; disclose drug and time |
| Riociguat | Separate contraindicated cGMP-related medicine | Review in general interaction assessment |
Some patients take isosorbide products regularly to prevent angina, while others carry sublingual nitroglycerin or a spray for intermittent chest symptoms. The absence of daily dosing does not remove the interaction risk: the issue is whether nitrate exposure and vardenafil use can overlap.
A complete pre-prescription history should ask specifically about emergency chest-pain medicines, not only pills taken every morning. The prescriber should review whether sexual activity and a PDE5 inhibitor are appropriate in the context of cardiovascular disease.
Recreational products sometimes called “poppers” may contain alkyl nitrites and should not be combined with vardenafil. Their use may not appear in formal medical records unless the patient mentions it explicitly, but it remains pharmacologically relevant.
A patient should give the clinician a candid account of all substances used. Unregulated labeling adds uncertainty rather than reducing risk. Neither a lower vardenafil strength nor a different tablet formulation makes the combination acceptable.
Chest pain following sexual activity or recent vardenafil can indicate a medical emergency. Stop activity and seek urgent medical assistance. Tell emergency responders and treating clinicians exactly which ED medicine was taken and approximately when, because routine chest-pain protocols may otherwise include nitrates.
Do not self-administer nitroglycerin or another nitrate after recent vardenafil and do not attempt to manage chest pain with online washout calculations. Qualified emergency clinicians must choose an appropriate evaluation and treatment plan.
Patients may search for a precise number of hours to wait between vardenafil and a nitrate. This page does not provide a home-managed clearance interval, because clinical risk and emergency decisions depend on drug formulation, other medications, health and the medical setting.
Vardenafil exposure can change markedly when potent CYP3A4 inhibitors are involved. A simple half-life calculation cannot certify nitrate safety. If a person requires nitrates, the prescriber needs to know before choosing ED therapy; if chest pain occurs, emergency clinical management takes precedence.
The film-coated label reports a small study in healthy subjects in which sublingual nitroglycerin effects were increased when given one or four hours after vardenafil 20 mg, with heart-rate effects at certain earlier time points. That potentiation was not observed when nitroglycerin followed the studied vardenafil dose by 24 hours. This observation does not establish a safe 24-hour waiting rule for people with ischemic heart disease: that population was not evaluated for this interaction, and the U.S. label explicitly states that a suitable safe interval has not been determined. Concurrent nitrate use remains contraindicated.
Many medical lists identify conditions such as coronary artery disease or angina without recording whether a rescue nitrate is carried. Ask the prescribing clinician and pharmacist to review the actual medicine names and instructions, including intermittent sprays, patches and any recently discontinued medicines.
This screening is relevant before the first fill and when medications change later. The prescription guide describes the wider medical history review; the result cannot be reduced to choosing an ED tablet strength from a chart.
The nitrate pathway is not the only interaction involving cGMP signaling. Riociguat, used for certain pulmonary-hypertension indications, is also contraindicated with vardenafil because the combination can significantly lower blood pressure.
A patient should not assume a medicine is irrelevant because it treats lung blood vessels rather than heart-related chest pain. The full medication list must be reviewed, including therapies from different specialists.
Severe dizziness, near-fainting, fainting, weakness, confusion or concerning chest discomfort can accompany a dangerous blood-pressure event. A suspected nitrate/vardenafil exposure warrants urgent professional help, rather than reassurance based on the absence of symptoms immediately after taking a medicine.
Do not drive yourself if you are faint or unstable. Provide emergency clinicians with product packaging or a medication list if available, including the time and amount taken as accurately as possible.
The most reliable prevention is to review contraindicated medicines before vardenafil is prescribed and each time relevant treatment changes. Prescriptions must be dispensed by a licensed pharmacy that checks the patient’s medication profile rather than bypassing the process through a no-prescription website.
This restriction applies to both film-coated and orally disintegrating vardenafil. For additional QT, alpha-blocker and CYP3A4 concerns, consult the interaction guide; for an evaluation of U.S. dispensing channels use the legal-access guide.
Someone who carries an as-needed nitrate for angina should tell every clinician involved in ED treatment, even if chest-pain episodes are infrequent. The possibility of needing urgent nitrate treatment changes the suitability assessment for a PDE5 inhibitor.
The appropriate alternative is not to stop carrying prescribed rescue medication or to conceal it in order to obtain vardenafil. Cardiovascular and ED care should be coordinated by qualified clinicians.
When speaking to emergency services, provide the exact ED medication name, formulation if known, approximate last administration time, the name of any nitrate medication, and other relevant medicines. A written or electronic medication list can help when the patient is unwell.
The immediate treatment decision belongs to emergency professionals. Online calculations based on average half-life cannot establish individual clearance or substitute for monitored care.
No. Nitrates and vardenafil are contraindicated together because they can cause severe hypotension.
Intermittent use remains relevant to the contraindication. Tell the prescriber about any rescue nitrate treatment.
Yes. Isosorbide mononitrate and dinitrate are organic nitrate medicines and must not be combined with vardenafil.
Yes. Alkyl nitrite products are medically relevant and should not be used with vardenafil.
No. The nitrate contraindication is not removed by choosing a lower strength.
No. Although a study in healthy volunteers did not show the same nitrate-potentiating effect 24 hours after a particular vardenafil dose, the U.S. label has not established a safe interval for patients. Nitrate treatment in an emergency belongs to clinicians, not a home washout calculation.
Seek emergency medical help immediately, disclose recent vardenafil use and do not self-administer a nitrate.
Yes. It is separately contraindicated because of excessive blood-pressure-lowering potential.